Sold as Staphcillin. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 15, 2026, FDA lists 2 applications for Methicillin Sodium (sold as Staphcillin), with 0 new uses approved and 0 published complete response letters.
| Gene Expression Analysis of Biofilm Formation and Antimicrobial Resistance in Clinical Methicillin-Resistant Staphylococcus AureusStaphylococcal Aureus Infection, Surgical Site Infection (SSI) · Sohag University | — | Not yet recruiting | Sep 1, 2026 |
| A Clinical Trial of Resistant Potato Starch for Gut MDRO DecolonizationClostridium Infections, Methicillin-resistant Staphylococcus Aureus (MRSA) · VA Office of Research and Development | Phase 2 | Not yet recruiting | Aug 28, 2026 |
| Evaluation of Safety and Efficacy of Phage Therapy for Drug-resistant Bacterial Infections: An Exploratory, Prospective Single-arm StudyUrinary Tract Infections, Urinary Tract Infections Caused by Drug-resistant Bacteria · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not applicable | Not yet recruiting | Feb 2, 2026 |
| Combination Antibiotic Therapy for Staphylococcus Aureus BacteremiaStaphylococcus Aureus Bacteremia · Intermountain Health Care, Inc. | Phase 4 | Recruiting | Jan 29, 2026 |
| Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus BacteremiaBacteriemia, Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection · Central Hospital, Nancy, France | — | Active, not recruiting | Sep 22, 2025 |
| Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA InfectionsMethicillin Resistant Staphylococcus Aureus, Osteomyelitis Acute · Indiana University | Phase 4 | Recruiting | May 21, 2025 |
| Linezolid Plus Standard of CareStaphylococcus Aureus Bloodstream Infections (BSI; Bacteremia) · University Hospital, Basel, Switzerland | Not applicable | Recruiting | May 6, 2025 |
| Comparative Analysis of Nemonoxacin and Other Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA) Antimicrobial Therapy in Patients With Complicated Skin and Soft Tissue Infections (cSSTI): a Retrospective Chart Review StudyMethicillin-susceptible S. Aureus (MSSA), Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA) · National Taiwan University Hospital | — | Active, not recruiting | May 6, 2025 |
| Apr 1, 1971 | StaphcillinANDA 61449 | Apothecon | 1 | Discontinued |
| — | StaphcillinNDA 50117 | Apothecon | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA